GYPA Antibody

What is Glycophorin A and why is it important in research?

Glycophorin A (GYPA) is a sialoglycoprotein of approximately 39 kDa present on red blood cells (RBCs) and erythroid precursor cells. It serves as the carrier of blood group M and N specificities and provides cells with a large mucin-like surface that may function as a barrier to cell fusion, minimizing aggregation between red blood cells in circulation. GYPA is particularly significant in research as it acts as a receptor for Sandei virus and parvovirus, making it valuable for studies on viral pathogenesis and cell-virus interactions . Additionally, GYPA's role as a cell surface marker makes it important for erythrocyte and erythroid precursor identification in hematological research .

What are the different types of GYPA antibodies available for research?

Researchers can utilize several types of GYPA antibodies, including:

• Polyclonal antibodies: These recognize multiple epitopes on the GYPA antigen, such as the Picoband® anti-Glycophorin A/GYPA antibody (A02184-2) which is rabbit-derived and reacts with human samples .

• Monoclonal antibodies: These recognize specific epitopes on GYPA, like the rabbit monoclonal antibody (M02184-1) that specifically targets human Glycophorin A (CD235a) .

• Recombinant monoclonal antibodies: These are engineered antibodies with consistent quality and specificity, such as the Glycophorin A/CD235a recombinant monoclonal rabbit antibody (GYPA/3219R) .

Each antibody type has distinct advantages depending on the experimental design and research questions being addressed.

How do GYPA antibodies differ in their applications across various research methods?

GYPA antibodies demonstrate versatility across multiple research applications:

The selection of the appropriate antibody and method depends on the specific research question, sample type, and desired sensitivity .

How should antigen retrieval be optimized when using GYPA antibodies for IHC of tissue samples?

For optimal antigen retrieval when using GYPA antibodies in immunohistochemistry:

• Buffer selection: Heat-mediated antigen retrieval works effectively with either citrate buffer (pH6) for polyclonal antibodies or EDTA buffer (pH8) for monoclonal antibodies .

• Duration: Perform antigen retrieval for 20 minutes at controlled temperature to ensure adequate epitope exposure without tissue damage .

• Blocking optimization: Block tissue sections with 10% goat serum to minimize non-specific binding, which is particularly important for highly vascularized tissues containing numerous erythrocytes .

• Antibody incubation: Incubate tissue sections with GYPA antibody (1 μg/ml for polyclonal or 1:100 dilution for monoclonal) overnight at 4°C to ensure specific binding while minimizing background .

• Secondary antibody selection: For polyclonal antibodies, biotinylated goat anti-rabbit IgG with Strepavidin-Biotin-Complex (SABC) development works effectively, while for monoclonal antibodies, Peroxidase Conjugated secondary antibodies are recommended .

These parameters should be further optimized based on the specific tissue type and fixation method employed.

Why do Western blot results show GYPA at 38kDa when the expected molecular weight is 16kDa?

The discrepancy between the observed molecular weight (38kDa) and the expected molecular weight (16kDa) of GYPA in Western blot analyses is primarily due to post-translational modifications, specifically extensive glycosylation . GYPA is a heavily glycosylated protein with approximately 60% of its mass composed of carbohydrates, particularly sialic acid residues .

When performing Western blot analysis for GYPA:

• Use appropriate positive controls (such as K562 cell lysates) that reliably express GYPA .

• Consider using gradient gels (5-20% SDS-PAGE) to better resolve the glycosylated form of the protein .

• Run electrophoresis under reducing conditions to ensure consistent protein denaturation and migration .

• If studying the protein core without glycosylation, consider enzymatic deglycosylation treatments prior to electrophoresis.

• When interpreting results, recognize that variations in glycosylation patterns may result in slight molecular weight differences between sample types .

This molecular weight discrepancy is a consistent finding across different antibodies and sample types, confirming that it represents a genuine characteristic of the GYPA protein rather than an experimental artifact .

How can GYPA antibodies be utilized for blood plasma separation in resource-constrained settings?

GYPA antibodies offer promising solutions for blood plasma separation in resource-constrained environments where centrifugation equipment may be unavailable:

• Antibody-based agglutination: Monoclonal antibodies against GYPA can bind and retain erythrocytes through hemagglutination, effectively separating cellular components from plasma without mechanical centrifugation .

• Implementation approaches:

  • Antibody-functionalized filter papers or membranes that capture erythrocytes while allowing plasma to flow through

  • Antibody-coated microfluidic devices that separate blood components through lateral flow principles

  • Paper-based diagnostic platforms incorporating anti-GYPA antibodies for point-of-care applications

• Methodological considerations:

  • Antibody concentration must be optimized to ensure complete erythrocyte capture without interfering with downstream analyses

  • Environmental stability (temperature, humidity) must be evaluated for field applications

  • Cross-reactivity with animal blood must be assessed if veterinary applications are considered

This application represents a significant advancement for diagnostic testing in low-resource settings, potentially improving healthcare access in underserved regions .

What are the considerations for using GYPA antibodies in studying erythroid differentiation and development?

When employing GYPA antibodies to investigate erythroid differentiation:

• Developmental expression patterns: GYPA expression increases during erythroid maturation, making it valuable for staging erythroid precursors when used in conjunction with other markers .

• Flow cytometry panel design:

  • Combine anti-GYPA (CD235a) with transferrin receptor (CD71) antibodies to distinguish between early and late erythroid precursors

  • Include additional markers such as CD45, CD34, and CD117 to fully characterize the erythroid differentiation stages

  • Select appropriate fluorophore conjugates (CF®488A, CF®568, etc.) based on your cytometer configuration and the abundance of target antigens

• Sample preparation protocols:

  • Use gentle fixation methods to preserve GYPA epitopes

  • Optimize red cell lysis buffers that don't damage nucleated erythroid precursors

  • Consider density gradient separation to enrich for nucleated erythroid populations

• Analysis strategies:

  • Implement appropriate gating strategies that account for the continuous nature of erythroid differentiation

  • Consider quantitative approaches to measure GYPA density as a marker of maturation

This application is particularly valuable for studying erythropoiesis in normal and pathological conditions, including anemias and erythroid leukemias .

How can researchers develop bi-specific antibodies incorporating anti-GYPA for therapeutic applications?

Developing bi-specific antibodies incorporating anti-GYPA domains requires:

• Strategic targeting design:

  • One arm targeting GYPA on erythrocytes

  • Second arm targeting disease-relevant antigens (pathogens, cancer cells, etc.)

  • Careful epitope selection to ensure accessibility and functionality in the bi-specific format

• Engineering approaches:

  • Antibody fragment coupling (e.g., Fab-scFv fusion)

  • Diabody or tandem scFv formats

  • Knobs-into-holes technology for full IgG bi-specifics

  • DNA recombination techniques for single-chain bi-specific constructs

• Functional validation assays:

  • Dual binding studies to confirm bi-specificity

  • Erythrocyte agglutination/binding assays to verify GYPA engagement

  • Target-specific functional assays for the second specificity

  • Blood compatibility and stability testing

• Application considerations:

  • Potential for erythrocyte-mediated drug delivery systems

  • Development of artificial antigen-presenting cells for immunotherapy

  • Clearance of pathogens by linking them to erythrocytes for liver degradation

This approach leverages the abundance and circulatory nature of erythrocytes as a platform for novel therapeutic strategies .

What strategies can resolve non-specific binding in tissues with high erythrocyte content?

When working with GYPA antibodies in highly vascularized tissues, non-specific binding can present significant challenges. The following methodological adjustments can improve specificity:

• Sample preparation optimization:

  • Perform thorough perfusion of animal tissues prior to fixation when possible

  • Utilize erythrocyte lysis buffers compatible with your fixation protocol

  • Consider shorter fixation times to minimize epitope masking

• Blocking protocol enhancement:

  • Extend blocking time to 2 hours with 10% serum from the same species as the secondary antibody

  • Add 0.1-0.3% Triton X-100 to blocking solution to improve penetration

  • Include additional blocking agents such as BSA (2-5%) or non-fat dry milk (3-5%)

• Antibody optimization:

  • Test multiple antibody dilutions in a broader range (1:50 to 1:1000)

  • Reduce primary antibody incubation temperature from 4°C to 1-2°C

  • Implement additional washing steps with higher salt concentration buffers

• Controls and validation:

  • Always include isotype controls to identify non-specific binding

  • Use tissues known to be negative for GYPA expression as negative controls

  • Consider using alternative GYPA antibody clones that may offer better specificity

These adjustments should be systematically tested and documented to establish an optimized protocol for your specific tissue type .

How can researchers distinguish between non-glycosylated and glycosylated forms of GYPA in experimental analyses?

Distinguishing between glycosylated and non-glycosylated GYPA forms requires specialized approaches:

• Enzymatic deglycosylation:

  • Treat samples with PNGase F to remove N-linked glycans

  • Use O-glycosidase with neuraminidase for O-linked glycan removal

  • Compare migration patterns before and after enzyme treatment

• Gradient gel optimization:

  • Employ 5-20% gradient SDS-PAGE gels for better resolution of different glycoforms

  • Run deglycosylated controls alongside native samples

  • Consider extended run times for improved separation

• Western blot detection strategies:

  • Use antibodies recognizing protein backbone epitopes rather than glycan-dependent epitopes

  • Compare detection patterns between antibodies recognizing different GYPA domains

  • Analyze migration patterns across multiple cell lines with variable glycosylation (K562, THP-1, U-87MG)

• Mass spectrometry approaches:

  • Perform glycopeptide analysis to characterize specific glycosylation sites

  • Compare peptide mass fingerprints before and after deglycosylation

  • Identify site-specific glycan compositions

Understanding these different forms is crucial for accurate interpretation of experimental results, particularly when studying GYPA in different cell types or disease states .

What novel applications are emerging for GYPA antibodies beyond traditional research methods?

Several innovative applications for GYPA antibodies are emerging in cutting-edge research:

• Point-of-care diagnostics:

  • Development of paper-based lateral flow assays utilizing anti-GYPA for blood fractionation

  • Microfluidic devices integrating GYPA antibody-coated channels for on-chip plasma separation

  • Portable diagnostic systems for resource-limited settings

• Advanced imaging applications:

  • Super-resolution microscopy of erythrocyte membrane organization using fluorophore-conjugated GYPA antibodies

  • Intravital imaging of erythrocyte dynamics using minimally disruptive anti-GYPA nanobodies

  • Correlative light-electron microscopy approaches for membrane protein organization studies

• Therapeutic developments:

  • Erythrocyte-targeted drug delivery systems using GYPA-binding fragments

  • Chimeric antigen receptor (CAR) T-cell therapy targeting aberrant GYPA expression in erythroleukemia

  • Bi-specific antibody platforms linking pathogens to erythrocytes for enhanced clearance

• Synthetic biology approaches:

  • Engineered erythrocytes with modified GYPA for extended circulation

  • Development of artificial blood substitutes with appropriate GYPA display

  • Cell-free protein expression systems for studying GYPA structure and function

These emerging applications represent the expanding utility of GYPA antibodies beyond traditional research and diagnostic applications .

How might cross-species reactivity of GYPA antibodies be leveraged for comparative hematology research?

While most commercially available GYPA antibodies are optimized for human samples, exploring cross-species reactivity offers valuable research opportunities:

• Evolutionary conservation assessment:

  • Sequence homology analysis between human GYPA and orthologs in model organisms

  • Epitope mapping to identify conserved regions across species

  • Testing existing human-specific GYPA antibodies against samples from diverse species

• Methodological approaches for cross-species validation:

  • Western blot analysis of erythrocyte lysates from multiple species

  • Flow cytometry with serial antibody dilutions to optimize detection

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Alternative fixation protocols that may better preserve cross-reactive epitopes

• Research applications leveraging cross-reactivity:

  • Comparative studies of erythrocyte development across species

  • Animal models of erythrocyte-associated pathologies

  • Evolutionary studies of blood group antigen development

  • Veterinary diagnostic tool development

A customer inquiry in the search results indicated interest in using anti-GYPA antibody A02184-2 for horse tissues, suggesting potential cross-reactivity that could be further explored and validated .